

New: Changes to Ontario’s Publicly Funded Pneumococcal Vaccine Program

Transitioning to Vaxneuvance® and Prevnar 20® Vaccines

See [page 7](#) for Ministry of Health resources.

AUGUST 2024

Ontario’s publicly funded pneumococcal vaccine program has transitioned to **two new pneumococcal vaccines – Pneu-C-15 (Vaxneuvance®) and Pneu-C-20 (Prevnar 20®)**.

- Pneu-C-13 (Prevnar 13®) and Pneu-P-23 (Pneumovax®) are being replaced.
- There are no current changes to eligibility and dosing schedule.
- Individuals with completed vaccine series are not part of the product transition.
- The product transitions are designed to provide long-term and broader protection against infections caused by pneumococcal bacteria.

Here’s an overview of the new vaccines for the age cohorts. As noted, **eligibility and dosing remain the same**.

Eligible Age Cohort	Risk of Invasive Pneumococcal Disease (IPD)	Current Publicly Funded Vaccine	New Publicly Funded Vaccine
6 weeks to 4 years	Low risk	Pneu-C-13	Pneu-C-15
6 weeks to 4 years	High risk	Pneu-C-13	
2 to 49 years	High risk	Pneu-P-23	
50 years of age and older	High risk	Pneu-C-13 and Pneu-P-23	Pneu-C-20
65 years of age and older	Low risk High risk	Pneu-P-23	

A reminder: dosing schedule for **routine** vaccination.

Dosing Schedule for Eligible Age Cohorts	What’s New	Guiding Principles	Recommended Pneu-C-15 / Pneu-C-20 Schedule According to History of Pneu-P-23 and/or Pneu-C-13 Immunization
Pediatric Vaccination – Routine Children 6 weeks to 4 years of age (up to fifth birthday) who are not at high risk of IPD.	Pneu-C-15 replaces Pneu-C-13.	If 0 doses or incomplete series, initialize or complete series with 1 or more doses of Pneu-C-15.	Up to 3 doses at 2, 4 and 12 months of age. If the series has already been completed with Pneu-C-13, the child is not eligible for doses of Pneu-C-15.
Adult Vaccination for ages ≥65 – Routine	Pneu-C-20 replaces Pneu-P-23.	May receive 1 dose of Pneu-C-20 if they have not received a dose of Pneu-P-23.	If the individual has already received Pneu-P-23, they are not eligible to receive a publicly funded dose of Pneu-C-20.



A reminder: dosing schedule for **those at high risk for invasive pneumococcal disease (IPD)**.

High-risk Criteria That Increase an Individual’s Risk for IPD

1. Asplenia (functional or anatomic), splenic dysfunction
2. Congenital (primary) immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
3. HIV infection
4. Immunocompromising therapy including use of long-term systemic corticosteroid, chemotherapy, radiation therapy, post-organ transplant therapy, certain antirheumatic drugs and other immunosuppressive therapy
5. Malignant neoplasms, including leukemia and lymphoma
6. Sickle-cell disease and other sickle cell hemoglobinopathies
7. Solid organ or islet cell transplant recipient
8. Hepatic cirrhosis due to any cause
9. Chronic renal disease, including nephrotic syndrome
10. Chronic cardiac disease
11. Chronic liver disease, including hepatitis B and C
12. Chronic respiratory disease, excluding asthma, except those treated with high-dose corticosteroid therapy
13. Chronic neurologic conditions that may impair clearance of oral secretions
14. Diabetes mellitus
15. Cochlear implant recipients (pre/post implant)
16. Chronic cerebral spinal fluid leak
17. Residents of nursing homes, homes for the aged and chronic care facilities or wards
18. Hematopoietic stem cell transplant (HSCT) recipient

Dosing for those at high risk (*cont’d*)

Select the age cohort and click the high-risk criteria in this table to go to the relevant dosing schedule.

Age 2 months to 59 months	Age 5 to 49 years	Age 50 to 64 years	Age 65 years and older
• <u>criteria #1 to #17</u>	• <u>criteria #1 to #9</u>	• <u>criteria #1 to #7</u>	• <u>criteria #1 to #7</u>
• <u>criteria #18</u>	• <u>criteria #10 to #17</u>	• <u>criteria #8 to #9</u>	• <u>criteria #8 to #9</u>
	• <u>criteria #18</u>	• <u>criteria #10 to #17</u>	• <u>criteria #10 to #17</u>
		• <u>criteria #18</u>	• <u>criteria #18</u>



<p>Pediatric Vaccination High-risk children aged 2 months to 59 months with criteria #1 to #17 (for this age cohort, criteria #17 refers to chronic care facilities or wards)</p>	<p>Pneu-C-20 replaces Pneu-C-13 and Pneu-P-23.</p>	<p>Pneu-C-20 should be given 1 year after previous dose of Pneu-P-23 (if applicable).</p>	<p>Up to 4 doses at 2, 4, 6 and 12 months of age*</p> <p>If the child has already received all their pneumococcal vaccines, they are not eligible for additional dose(s) of Pneu-C-20.</p> <p>*Except for hematopoietic stem cell transplantation (HSCT) recipients. See more information below.</p> <p>2 to 6 months</p> <p>0 doses</p> <ul style="list-style-type: none"> • 1st dose at age \geq 2 months • 2nd dose, 2 months after 1st dose • 3rd dose, 2 months after 2nd dose • 4th dose, 2 months after 3rd dose and at age 12-15 months <p>1 dose (1st dose)</p> <ul style="list-style-type: none"> • 2nd dose, 2 months after 1st dose • 3rd dose, 2 months after 2nd dose • 4th dose, 2 months after 3rd dose and at age 12-15 months <p>7 to 11 months</p> <p>0 doses</p> <ul style="list-style-type: none"> • 1st dose • 2nd dose, 2 months after 1st dose • 3rd dose, 2 months after 2nd dose and at age 12-15 months <p>1 dose (1st dose)</p> <ul style="list-style-type: none"> • 2nd dose, 2 months after 1st dose • 3rd dose, 2 months after 2nd dose and at age 12-15 months <p>2 doses (1st and 2nd doses)</p> <ul style="list-style-type: none"> • 3rd dose, 2 months after 2nd dose and at age 12-15 months <p>12 to 23 months</p> <p>0 doses</p> <ul style="list-style-type: none"> • 1st dose • 2nd dose, 2 months after 1st dose
--	--	---	---



<p>Pediatric Vaccination (cont'd)</p>			<p>1 dose (1st dose) at age <12 months</p> <ul style="list-style-type: none"> • 2nd dose, 2 months after 1st dose • 3rd dose, 2 months after 2nd dose <p>1 dose (1st dose) at age ≥ 12 months</p> <ul style="list-style-type: none"> • 2nd dose, 2 months after 1st dose <p>1 dose (1st dose) at age <12 months + 1 dose (2nd dose) at age ≥ 12 months</p> <ul style="list-style-type: none"> • 3rd dose, 2 months after 2nd dose <p>2 or more doses at age <12 months</p> <ul style="list-style-type: none"> • 1 dose, 2 months after most recent dose <p>24 to 59 months</p> <p>0 doses</p> <ul style="list-style-type: none"> • 1 dose <p>Any incomplete series</p> <ul style="list-style-type: none"> • 1 dose, 2 months after most recent dose
<p>Vaccination for High-risk Individuals Aged 5 to 49 Years with criteria #1 to #9 in list above</p>	<p>Pneu-C-20 replaces Pneu-C-13 and Pneu-P-23.</p>		<p>0 to 1 dose of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose (if applicable) <p>2 doses of Pneu-P-23</p> <ul style="list-style-type: none"> • None
<p>Vaccination for High-risk Individuals Aged 5 to 49 Years with criteria #10 to #17 in list above</p>	<p>Pneu-C-20 replaces Pneu-C-13 and Pneu-P-23.</p>		<p>0 doses of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) <p>1 dose of Pneu-P-23</p> <ul style="list-style-type: none"> • None
<p>Vaccination for High-risk Individuals Aged 50 to 64 Years with criteria #1 to #7 in list above</p>	<p>Pneu-C-20 replaces Pneu-P-23 and Pneu-C-13.</p>		<p>0 to 2 doses of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last doses of Pneu-P-23 (if applicable) <p>0 to 1 dose of Pneu-P-23 and 1 dose of Pneu-C-13</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) and 8 weeks after last dose of Pneu-C-13 <p>2 doses of Pneu-P-23 and 1 dose of Pneu-C-13</p> <ul style="list-style-type: none"> • None



<p>Vaccination for High-risk Individuals Aged 50 to 64 Years with criteria #8 to #9 in list above</p>	<p>Pneu-C-20 replaces Pneu-P-23. Previously not eligible for Pneu-C-13.</p>		<p>0 to 1 dose of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) <p>2 doses of Pneu-P-23</p> <ul style="list-style-type: none"> • None
<p>Vaccination for High-risk Individuals Aged 50 to 64 Years with criteria #10 to #17 in list above</p>	<p>Pneu-C-20 replaces Pneu-P-23. Previously not eligible for Pneu-C-13</p>		<p>0 doses of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) <p>1 dose of Pneu-P-23</p> <ul style="list-style-type: none"> • None
<p>Post-transplant Vaccination for Hematopoietic Stem Cell Transplantation (HSCT) Recipients (Criteria #18)</p> <ul style="list-style-type: none"> • Aged 6 weeks to 4 years • Aged 5 to 64 years 	<p>Pneu-C-20 replaces Pneu-C-13.</p>	<p>Have not completed or have not started their Pneu-C-13 vaccine series\ post-transplant.</p>	<p>0 doses of Pneu-C-13 post HSCT</p> <ul style="list-style-type: none"> • 1st dose, 3-9 months post HSCT • 2nd dose, 4 weeks after 1st dose • 3rd dose, 4 weeks after 2nd dose • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose <p>1 dose of Pneu-C-13 post HSCT (1st dose)</p> <ul style="list-style-type: none"> • 2nd dose, 4 weeks after 1st dose • 3rd dose, 4 weeks after 2nd dose • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose <p>2 doses of Pneu-C-13 post HSCT (1st and 2nd doses)</p> <ul style="list-style-type: none"> • 3rd dose, 4 weeks after 2nd dose • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose <p>3 doses of Pneu-C-13 post HSCT (1st, 2nd and 3rd dose)</p> <ul style="list-style-type: none"> • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose



<p>Vaccination for High-risk Individuals Aged ≥ 65 years with criteria #1 to #7 in list above</p>	<p>Pneu-C-20 replaces Pneu-P-23. Previously may not have been eligible for Pneu-C-13.</p>		<p>0 to 3 doses of Pneu-P-23 and 0 doses of Pneu-C-13 or 0 to 2 doses of Pneu-P-23 and 1 dose of Pneu-C-13</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) and last dose of Pneu-C-13 <p>3 doses of Pneu-P23, with at least 1 dose at age ≥ 65 years and 1 dose of Pneu-C-13</p> <ul style="list-style-type: none"> • None
<p>Vaccination for High-risk Individuals Aged ≥ 65 years with criteria #8 to #9 in list above</p>	<p>Pneu-C-20 replaces Pneu-P-23. Previously not eligible for Pneu-C-13.</p>		<p>0 to 2 doses of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose <p>3 doses of Pneu-P23, with at least 1 dose at age ≥ 65 years</p> <ul style="list-style-type: none"> • 0 doses
<p>Vaccination for High-risk Individuals Aged ≥ 65 years with criteria #10 to #17 in list above</p>	<p>Pneu-C-20 replaces Pneu-P-23. Previously not eligible for Pneu-C-13.</p>		<p>0 to 1 dose of Pneu-P-23</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) <p>2 doses of Pneu-P-23 with at least 1 dose at age ≥ 65 years</p> <ul style="list-style-type: none"> • None
<p>Post-transplant Vaccination for Hematopoietic Stem Cell Transplantation (HSCT) Recipients Aged ≥ 65 years (Criteria #18)</p>	<p>Pneu-C-20 replaces Pneu-C-13.</p>	<p>Dose(s) of Pneu-C-20 should be given 1 year after last dose of Pneu-P-23, if applicable.</p>	<p>0 to 3 doses of Pneu-P-23 and 0 doses or incomplete series of Pneu-C-13</p> <p>0 doses or incomplete series of Pneu-C-13 post HSCT</p> <ul style="list-style-type: none"> • 1st dose, 3-9 months post HSCT • 2nd dose, ≥ 4 weeks after 1st dose • 3rd dose, ≥ 4 weeks after 2nd dose • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose <p>1 dose of Pneu-C-13 post HSCT (1st dose)</p> <ul style="list-style-type: none"> • 2nd dose, ≥4 weeks after 1st dose • 3rd dose, ≥ 4 weeks after 2nd dose • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose



<p>Post-transplant Vaccination for Hematopoietic Stem Cell Transplantation (HSCT) Recipients Aged ≥ 65 years (Criteria #18) (cont'd)</p>			<p>2 doses of Pneu-C-13 post HSCT (1st and 2nd doses)</p> <ul style="list-style-type: none"> • 3rd dose, ≥ 4 weeks after 2nd dose • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose <p>3 doses of Pneu-C-13 post HSCT (1st, 2nd and 3rd dose)</p> <ul style="list-style-type: none"> • 4th dose, 12-18 months post-transplant and 6-12 months after 3rd dose <p>0 to 2 doses of Pneu-P-23 and completed series of Pneu-C-13</p> <ul style="list-style-type: none"> • 1 dose, 1 year after last dose of Pneu-P-23 (if applicable) and 8 weeks after last dose of Pneu-C-13 <p>3 doses of Pneu-23 and completed series of Pneu-C-13</p> <ul style="list-style-type: none"> • None
---	--	--	--

Ministry of Health Resources | Sources

- [Qs & As for Health Care Providers: Pneumococcal Vaccine Transition](#)
- [Health Care Provider Fact Sheet: Pneumococcal Conjugate Vaccine for Children Aged 6 Weeks to 4 Years](#)
- [Health Care Provider Fact Sheet: Pneumococcal Conjugate Vaccine for Individuals Aged 5 to 64 Years at High Risk for Invasive Pneumococcal Disease](#)
- [Health Care Provider Fact Sheet: Pneumococcal Conjugate Vaccine for Individuals Aged 65 Years and Older](#)
- [Publicly Funded Immunization Schedule for Ontario](#)